The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: A literature review and meta-analysis

Rheumatology

Volumn 48, Issue 7, 2009, Pages 791-795

  Malenfant, Deanne ^a   Catton, Michelle ^b   Pope, Janet E ^a,c,d  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d NONE   (Canada)

Author keywords

Acupuncture; Anti oxidants; Biofeedback; Complementary and alternative medicine; Laser; Meta analysis; Raynaud's phenomenon

Indexed keywords

ALLOPURINOL; ANTIOXIDANT; ARGININE; ASCORBIC ACID; BIO ANTOX; ESSENTIAL FATTY ACID; FISH OIL; GINKGO BILOBA EXTRACT; GLYCOSAMINOGLYCAN; PLACEBO; PRIMROSE OIL; UNCLASSIFIED DRUG;

ACUPUNCTURE; ALTERNATIVE MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEEDBACK SYSTEM; GENETIC HETEROGENEITY; HUMAN; LOW LEVEL LASER THERAPY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; REVIEW; THERAPEUTIC GLOVES; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

COMPLEMENTARY THERAPIES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAYNAUD DISEASE; TREATMENT FAILURE;

EID: 67650079787     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep039     Document Type: Review

References (27)

1. Pope JE. The diagnosis and treatment of Raynaud's phenomenon: A practical approach. Drugs 2007;67:517-25.
2. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis. Rheumatology 2005;44:145-50.
3. Belch JJ, Ho M. Pharmacotherapy of Raynaud's phenomenon. Drugs 1996; 52:682-95.
4. Appiah R, Hiller S, Caspary L, Alexander K, Creutzig A. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med 1997;241:119-24.
5. DiGiacomo RA, Kremer JM, Shad DM. Fish-oil dietary supplementation in patients with Raynaud's: A double-blind, controlled, prospective study. Am J Med 1989;68:158-64.
6. Muir AH, Robb R, McLaren M, Daly F, Belch JJ. The use of Ginkgo biloba in Raynaud's disease: A double-blind placebo controlled trial. Vasc Med 2002;7:265-7.
7. National Center for Complementary and Alternative Medicine: http://nccam.nih.gov/health/whatiscam/ (1 March 2008, date last accessed).
8. Altman DG, Schultz KF, Moher D et al. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med. 2001;34:663-94.
9. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.0.0 [updated February 2008]. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2008 (1 March 2008, date last accessed).
10. Signorini GP. [A double-blind clinical trial of a topical preparation with a base of biochemical precursors of glucosaminoglycan (GAG) in patients suffering from Raynaud's disease.]. Boll Chim Farm 1986;125:103S-10S.
11. Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: Randomized, placebo-controlled study. Altern Med Rev 2002;7:328-35.
12. Khan F, Litchfield SJ, McLaren M, Veale DJ, Littleford RA, Belch JJ. Oral L-arginine supplementation and cutaneous vascular response in patients with primary Raynaud's phenomenon. Arthritis Rheum 1997;40:352-7.
13. Khan F, Belch JJ. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: Effect of oral L-arginine supplementation. J Rheumatol 1999; 26:2398-94.
14. Mavrikakis ME, Lekakis JP, Papamichael CM, Stamatelopoulos KS, Kostopoulos ChC, Stamatelopoulos SF. Ascorbic acid does not improve endothelium-dependant flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis. Int J Vitam Nutr Res 2003;73:3-7.
15. Herrick AL, Hollis S, Schofild D et al. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000;18:349-56.
16. Hahn M, Steins A, Mörle M, Blum A, Jünger M. Gibt es einen vasospasmolytischen effekt der akupunctur bei patienten mit sekundärem raynaud-phänomen? [Is there a vasospasmolytic effect of acupuncture in patients with secondary Raynaud's phenomenon?]. J Dtsch Dermatol Ges 2004;2:758-62.
17. Stainforth JM, Layton AM, Good field MJD. Clinical aspects of the use of gamma linolenic acid in systemic sclerosis. Acta Derm Venereol 1996;76:144-6.
18. Belch JJ, Shaw B, O'Dowd A et al. Evening primrose oil (efamol) in the treatment of Raynaud's phenomenon: A double-blind study. J Thromb Haemost 1985;54:490-4.
19. al-Awami M, Schillinger M, Maca T, Pollanz S, Minar E. Low level laser therapy treatment of primary and secondary Raynaud's phenomenon. VASA 2004;33:25-9.
20. Hirschl M, Katzenschlager R, Francesconi C, Kundi M. Low level laser therapy in primary Raynaud's phenomenon - results of a placebo controlled, double blind intervention study. J Rheumatol 2004;31:2408-12.
21. Hirschl M, Katzenschalger R, Ammer K, Melnizki P, Rathklb O, Kundi M. Double-blind, randomized, placebo-controlled low level laser therapy study in patients with primary Raynaud's phenomenon. VASA 2002;31:91-4.
22. Büttner M, Henschel G, Spengel FA. Wirksamkeit von temperatur-biofeedback in der therapie des Morbus Raynaud. [Effectiveness of temperature biofeedback in therapy of Raynaud's disease]. Vasc Suppl 1991;32:411-5.
23. Freedman RR, Ianni P, Wenig P. Behavioural treatment of Raynaud's phenomenon in scleroderma. J Behav Med 1984;7:343-51.
24. Guglielmi RS, Roberts AH, Patterson R. Skin temperature biofeedback for Raynaud's disease: A double-blind study. Biofeedback Self Regul 1982;7:99-120.
25. Jobe JB, Sampson S, Roberts DE, Kelly JA. Comparison of behavioral treatments for Raynaud's disease. J Behav Med 1986;9:89-96.
26. Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon. Arch Intern Med 2000;160:1101-8.
27. Merkel P, Herlyn K, Martin RW, Anderson JJ, Mayes MD. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.